Sanguila, Lynde P.

HRN: 22-11-16  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/27/2022
CEFUROXIME 1.5GM (VIAL)
10/27/2022
11/03/2022
IV
1.5gms
Q8H
UTI, Uncomplicated
10/27/2022
CEFUROXIME 500MG (TAB)
10/27/2022
10/31/2022
ORAL
500mg
BID
UTI
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

 Indication:

              

 Type of Infection:

                             

           

 Compliance to guidelines:



 Initial appropriateness:



 If inappropriate:

           

 Final appropriateness:



 If inappropriate:

              

 Overall appropriateness: